BioTech 365

JULY 28, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: GSK culls phase 2 RSV vaccine in kids, as feladilimab flops again, this time in lung cancer.GSK culls phase 2 RSV vaccine in kids, as feladilimab flops … Continue reading →

Vaccination 40

Vaccination Vaccine Research 40

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

BioTech 365

NOVEMBER 24, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Hoping for an endgame, GSK kick-starts phase 3 RSV vaccine trial in pregnant women.Hoping for an endgame, GSK kick-starts phase 3 RSV vaccine trial in pregnant women … Continue reading →

Vaccination 40

Vaccination Vaccine Trials Research 40

Medical Xpress

DECEMBER 22, 2022

The News & Observer spoke with Dr. David Weber, associate chief medical officer at UNC Medical Center and medical director of UNC's Department of Infection Prevention, to learn more about RSV, a common virus affecting many this fall and winter.

Doctors 98

Doctors Doctor 98

pharmaphorum

DECEMBER 15, 2022

However, this has led to increased transmission of other respiratory diseases and, as we’re already seeing, there are now some very real concerns about a lesser-known virus – respiratory syncytial virus, or RSV. RSV is one of the most common respiratory viruses, causing coughs and colds during the winter months.

Scientist 67

Scientist Research Vaccination Vaccine 67

pharmaphorum

NOVEMBER 2, 2022

. “We are again raising our full-year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks, driven by Shingrix global expansion and expected new launches, including our new RSV vaccine,” said GSK’s chief executive Emma Walmsley (pictured above).

Vaccination 85

Vaccination Vaccine Sales Marketing 85

Drug Discovery World

JUNE 16, 2023

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas. GSK faces RSV vaccine threat from rival Pfizer An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market.

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 28, 2022

The EMA has delivered some good news to GSK on a new long-acting HIV drug and vaccine for respiratory syncytial virus (RSV), in a week that saw multiple disappointments in other R&D projects. Those developments have placed much more onus on other projects – and particularly GSK’s RSV vaccine – to deliver quickly.

Regulation 52

Regulation Vaccination Vaccine Sales 52

pharmaphorum

DECEMBER 22, 2022

“It is vital we invest in fighting future variants of this disease, as well as other deadly viruses that are circulating, such as seasonal flu and RSV, and this partnership with Moderna will also strengthen our ability to respond to any future pandemics,” said Health and Social Care secretary, Steve Barclay.

Vaccination 118

Vaccination Vaccine Life Science Manufacturing 118

XTalks

OCTOBER 26, 2023

The season also marks the increased circulation of other respiratory viruses, including SARS-CoV-2, which causes COVID-19, and respiratory syncytial virus (RSV). And now, RSV vaccines will also be available for the first time this fall. This includes the emergence of new variants and vaccination strategies.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

OCTOBER 21, 2022

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer . Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens. . New antibiotic could kill resistant pathogens .

Drugs 52

Drugs Allergies Clinical Trials Clinical Trials 52

XTalks

DECEMBER 20, 2023

Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device. Read on to see our editorial team’s top news picks of the year.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

FEBRUARY 12, 2024

The ad features paintings, photos and statues of famous scientists throughout the times, including Isaac Newton, Galileo, Rosalind Franklin, Marie Maynard Daly, Albert Einstein and Pfizer founders Charles Pfizer and Charles Erhart singing to Queen’s “Don’t Stop Me Now.”

Scientist 105

Scientist DNA Vaccination Vaccine 105

Pfizer

OCTOBER 18, 2022

Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review RSV Data Presented at ID Week 2022. Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review RSV Data Presented at ID Week 2022. NEW YORK, October 17, 2022— Pfizer Inc. Tue, 10/18/2022 - 09:04. 10.17.2022.

Vaccination 40

Vaccination Vaccine Gene Therapy Medicine 40

Drug Discovery World

JANUARY 9, 2023

As well as Covid-19 vaccines, the deal will include vaccines developed for other respiratory diseases, such as flu and respiratory syncytial virus (RSV). . It is an important reminder that the Life Sciences Industry has the potential to be a key growth driver for the UK economy.” .

Research 52

Research Vaccination Vaccine Trials 52

XTalks

JANUARY 11, 2023

It is the most transmissible variant that has been detected yet,” Maria Van Kerkhove, the COVID-19 technical lead at the World Health Organization (WHO), said during a news conference last week. The new subvariant has also been dubbed “Kraken” by some scientists. While the XBB.1.5 Nonetheless, it has been found in 29 countries so far.

Scientist 98

Scientist Vaccination Vaccine Genetics 98

pharmaphorum

OCTOBER 12, 2022

Share in Moderna rose around 9% after the news was announced, as investors welcomed the progress in the biotech’s pipeline beyond its COVID-19 vaccine, which is predicted to make around $21 billion in sales this year but is its only commercial product and could see orders fall if the pandemic comes under control.

Vaccination 93

Vaccination Vaccine Gene Sequencing RNA 93

pharmaphorum

AUGUST 6, 2021

There was also encouraging news on the clinical side, with the final analysis of the phase 3 COVE study of SpikeVax showing 93% efficacy six months after the second dose, and mid-stage trials of third-dose boosters showing good responses against SARS-CoV-2 variants of concern. It has completed enrolment in a phase 1 trial of the jab.

Sales 104

Sales Vaccination Vaccine Antibody 104

XTalks

AUGUST 19, 2020

Additionally, weekly influenza numbers and respiratory syncytial virus (RSV) infections in children were recorded, nationwide, and were compared to numbers from 2015. Children under the age of one are also frequently hospitalised due to RSV or influenza. Animals practice social distancing to protect themselves from disease.

Genetic Disease 111

Genetic Disease Genetics Life Science Research 111

Drug Discovery World

FEBRUARY 13, 2023

Meanwhile, Poolbeg Pharma and OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an AI programme. Using AI, researchers at Chalmers University of Technology, Sweden succeeded in designing synthetic DNA that controls the cells’ protein production.

Genome 52

Genome Genomics Life Science Drugs 52

The Pharma Data

OCTOBER 19, 2020

News information is not all-inclusive and updates are published once a week on Tuesdays. . . New Guidance: The FDA issued and implemented new guidance, Enforcement Policy for Modifications to FDA-Cleared Molecular Influenza and RSV Tests During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. FDA Actions.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

XTalks

OCTOBER 31, 2023

GlaxoSmithKline (GSK) Canada has roped in both older and younger versions of Wayne Gretzky for a new ad for its respiratory syncytial virus (RSV) vaccine Arexvy. The 30-second video ad features a young, AI-generated Wayne Gretzky cautioning his older self today about the dangers of RSV, particularly for older adults.

Vaccination 97

Vaccination Vaccine FDA Approval Development 97

XTalks

MAY 5, 2023

This week, the US Food and Drug Administration (FDA) approved the world’s first respiratory syncytial virus (RSV) vaccine. GSK says the RSV vaccine will be available for older adults before this year’s RSV season, which usually starts before the winter months. RSV is a negative-strand RNA virus that was first identified in 1955.

Vaccination 105

Vaccination Vaccine FDA Approval Development 105

pharmaphorum

MARCH 3, 2022

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market that will protect infants from the life-threatening infection. The post After GSK stumble, Pfizer moves forward with RSV vaccine appeared first on.

Vaccination 52

Vaccination Vaccine Antibody Trials 52

XTalks

FEBRUARY 5, 2024

In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo. Going up against vaccine stalwart Pfizer wasn’t an easy feat but GSK succeeded in the challenge by taking an early lead in the RSV vaccine battle. billion or £1.2

Vaccination 59

Vaccination Vaccine Marketing Sales 59

XTalks

MAY 10, 2023

Just ahead of having nabbed a historic approval for its respiratory syncytial virus (RSV) vaccine, GlaxoSmithKline (GSK) launched ad campaigns to promote RSV awareness, particularly among older adults. This includes the ‘Cut Short by RSV’ and ‘Sideline RSV’ campaigns launched in April and March, respectively.

FDA Approval 98

FDA Approval Vaccination Vaccine Development 98

XTalks

FEBRUARY 3, 2021

Shots from both companies could also offer protection against some of the new circulating variants of SARS-CoV-2, which is welcome news in light of their increasing spread around the world. The company’s HIV, RSV and Zika vaccine candidates were also generated using the AdVac technology platform. Novavax’s Protein Vaccine.

Vaccination 103

Vaccination Vaccine Trials Protein 103

pharmaphorum

SEPTEMBER 18, 2020

“Picking the next merger candidate is hard enough, doing so before everyone else jumps on board, then picking the right time to sell makes for a dangerous investment game,” said one BBC News article from December 1998. For the latest news from AstraZeneca, click here. Blockbusters go off patent. Pascal Soriot. Pfizer makes its move.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

XTalks

NOVEMBER 4, 2022

Pfizer announced positive top-line data from a Phase III trial evaluating its respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF (or PF-06928316) for pregnant individuals to help protect their infants from RSV disease after birth. Related: Pfizer to Acquire RSV Antiviral Developer ReViral in $525 Million Deal.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

SEPTEMBER 16, 2022

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. In part, that is because of the scale of the public health crisis caused by RSV. In the US, Synagis is sold by Sobi.

Antibody 57

Antibody Vaccination Vaccine Marketing 57

XTalks

SEPTEMBER 22, 2023

Related: Arexvy Becomes World’s First RSV Vaccine The updated COVID vaccines will not be bought by the government like before. This fall will mark the first time vaccines will be rolled out for three major respiratory viruses: influenza, SARS-CoV-2 and respiratory syncytial virus (RSV).

Vaccination 59

Vaccination Vaccine FDA Approval Pharmacy 59

Scienmag

MAY 19, 2022

Peer-reviewed/Literature review and Modelling/People Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) contributes substantially to the global mortality burden in children, with RSV estimated to cause one in 50 deaths among children under five, and one in 28 deaths among children under six months.

66

66

XTalks

APRIL 14, 2022

Pfizer hopes the purchase will help bolster its respiratory syncytial virus (RSV) pipeline by adding several of ReViral’s “promising” candidate RSV antiviral therapeutics. Treatment options for RSV are limited and primarily focus on supportive care. Treatment options for RSV are limited and primarily focus on supportive care.

Development 52

Development Vaccination Vaccine Protein 52

Scienmag

FEBRUARY 27, 2022

With that in mind, researchers investigated its potential to prevent future recurrent wheezing among infants hospitalized with respiratory syncytial virus (RSV). The antibiotic azithromycin has anti-inflammatory properties that can be beneficial in some chronic lung diseases, such as cystic fibrosis.

Scientist 64

Scientist Development Research 64

Scienmag

FEBRUARY 27, 2022

Findings from a recent study evaluating the impact of the antibiotic azithromycin during severe respiratory syncytial virus (RSV) bronchiolitis overwhelmingly support current national bronchiolitis guidelines, which recommend against antibiotics during acute bronchiolitis due to lack of effect on the acute illness.

58

58

Scienmag

JANUARY 27, 2022

FOR IMMEDIATE RELEASE Contact: Michael Saunders, msaunder@bu.edu Jillian McKoy, jpmckoy@bu.edu ## BU Study: Infant Deaths from RSV Are Much Higher than Previously Known A new study found that nearly one in ten of all deceased infants under 6 months old were infected with Respiratory Syncytial Virus (RSV).

48

48

Scienmag

MARCH 14, 2022

Washington, DC / New Delhi, India […].

Vaccination 69

Vaccination Vaccine 69